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Background: Focal segmental glomerulosclerosis (FSGS) is a major cause of end-stage renal disease. Recent studies
have proposed that plasma soluble urokinase receptor (suPAR) might be a causative circulating factor but this
proposal has caused controversy. This study aimed to measure urinary suPAR levels in patients with primary FSGS
and its significance in the pathogenesis of FSGS.
Methods: Sixty-two patients with primary FSGS, diagnosed between January 2006 and January 2012, with
complete clinical and pathologic data were enrolled, together with disease and normal controls. Urinary suPAR
levels were measured using commercial ELISA kits and were corrected by urinary creatinine (Cr). The associations
between urinary suPAR levels and clinical data at presentation and during follow up were analyzed. Conditionally
immortalized human podocytes were used to study the effect of urinary suPAR on activating β3 integrin detected
by AP5 staining.
Results: The urinary suPAR level of patients with primary FSGS (500.56, IQR 262.78 to 1,059.44 pg/μmol Cr) was
significantly higher than that of patients with minimal change disease (307.86, IQR 216.54 to 480.18 pg/μmol Cr,
P = 0.033), membranous nephropathy (250.23, IQR 170.37 to 357.59 pg/μmol Cr, P <0.001), secondary FSGS
(220.45, IQR 149.38 to 335.54 pg/μmol Cr, P <0.001) and normal subjects (183.59, IQR 103.92 to 228.78 pg/μmol Cr,
P <0.001). The urinary suPAR level of patients with cellular variant was significantly higher than that of patients with
tip variant. The urinary suPAR level in the patients with primary FSGS was positively correlated with 24-hour urine
protein (r = 0.287, P = 0.024). During follow up, the urinary suPAR level of patients with complete remission
decreased significantly (661.19, IQR 224.32 to 1,115.29 pg/μmol Cr versus 217.68, IQR 121.77 to 415.55 pg/μmol Cr,
P = 0.017). The AP5 signal was strongly induced along the cell membrane when human differentiated podocytes
were incubated with the urine of patients with FSGS at presentation, and the signal could be reduced by a blocking
antibody specific to uPAR.
Conclusions: Urinary suPAR was specifically elevated in patients with primary FSGS and was associated with
disease severity. The elevated urinary suPAR could activate β3 integrin on human podocytes.
Please see related article http://www.biomedcentral.com/1741-7015/12/82.
Keywords: Focal segmental glomerulosclerosis, Urinary soluble urokinase receptor, Podocyte* Correspondence: mhzhao@bjmu.edu.cn
1Renal Division, Peking University First Hospital, Beijing, PR China
2Institute of Nephrology, Peking University, Beijing, PR China
Full list of author information is available at the end of the article
© 2014 Huang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Huang et al. BMC Medicine 2014, 12:81 Page 2 of 11
http://www.biomedcentral.com/1741-7015/12/81Background
Focal segmental glomerulosclerosis (FSGS), which was
first described by Rich in an autopsy series [1], is defined
as a clinico-pathological syndrome manifesting with pro-
teinuria, usually of nephrotic range, and pathological le-
sions of focal and segmental glomerular sclerosis and
diffuse foot-process effacement [2,3]. FSGS is divided
into either primary form (without known cause) or sec-
ondary to other kidney injuries, such as genetic variations,
increased intra-glomerular pressures, reflux disease, vi-
ruses, drug toxicity and so on [4]. For primary FSGS, the
etiology and pathogenesis have not been well elucidated,
but the damage and detachment of podocytes from the
glomerular basement membrane are regarded as the key
in the initiation and progression of FSGS [5,6]. Previous
studies have reported that secondary FSGS caused by gen-
etic mutation usually did not recur following kidney trans-
plantation, but in some patients with primary FSGS, it
may recur within hours after kidney transplantation [7].
Some patients with primary FSGS were successfully trea-
ted with plasmapheresis or immunoabsorption [8,9], and a
circulating permeability factor has been proposed in those
patients [10,11]. Recently, Wei et al. found that soluble
urokinase receptor (suPAR) might be the most likely
causative circulating factor for primary FSGS [12]. Our
previous study also revealed that elevated plasma suPAR
might be specific for some patients with primary FSGS
[13]. Other studies, however, have indicated that plasma
suPAR might not be a specific marker for primary or idio-
pathic FSGS [14] and that it is unlikely to be the leading
cause of childhood primary FSGS [15]. A recent study
suggested that the urinary suPAR level might be a better
biomarker than the plasma suPAR level in predicting the
recurrence of FSGS after transplantation [16]. Our current
study measured the urinary suPAR level in a variety of
primary glomerular diseases, including primary FSGS
with various pathological variants; we also analyzed its
clinical significance and further investigated the pos-




According to the definition of primary FSGS in the
Columbia classification [3], 62 patients with primary
FSGS with complete clinical and pathological data, diag-
nosed in Peking University First Hospital between January
2006 and January 2012, were enrolled in this study. FSGS
secondary to other primary glomerular diseases, such as
IgA nephropathy, lupus nephritis, pauci-immune glome-
rulonephritis, membranous nephropathy, were excluded.
All patients were negative for anti-neutrophil cystoplas-
mic antibody. The pathological variants of the 62 pa-
tients with primary FSGS include 19 tip variant, 21 nototherwise specified (NOS) variant, 20 cellular variant,
1 perihilar variant, and 1 advanced FSGS. The clinical
and pathological data were collected at the time of pres-
entation. Twenty eight patients had the last follow-up
data, and none of them required kidney transplant. We
collected urine samples from 16 patients with thera-
peutic responses.
Patients with nephrotic syndrome, defined as urinary
protein excretion greater than or equal to 3.5 g/24 hours
with serum albumin less than 30 g/L, were treated with
corticosteroid combined with immunosuppressive agents
including cyclophosphamide and cyclosporine A. Oral
prednisone began at 1 mg/kg/day for up to 12 to 16
weeks followed by subsequent tapering, oral cyclophos-
phamide at 1.5 to 2 mg/kg/day for three months or
cyclosporine A at 2 to 3 mg/kg/day with a trough con-
centration around 100 to 150 μg/ml, for 6 to 12 months.
All patients were treated with angiotensin-converting
enzyme inhibitors and/or angiotensin receptor blockers.
For evaluation of the therapeutic response of patients
with nephrotic syndrome, complete remission was de-
fined as proteinuria less than or equal to 0.15 g/24 hours
with stable serum Cr (no more than 25% increase in
serum level from baseline). Partial remission was defined
as proteinuria less than 3.5 g/24 hours but greater than
0.15 g/24 hours, with stable renal function in patients
presenting with nephrotic syndrome. Treatment failure
was defined as not reaching the criteria of partial remis-
sion. Patients who achieved partial remission and pa-
tients with treatment failure were collectively named the
non-complete remission group.
Thirteen patients with minimal change disease, 22 pa-
tients with membranous nephropathy, 13 patients with
secondary FSGS and 26 age- and gender-matched nor-
mal subjects were used as disease and normal controls.
According to Hepinstall’s Pathology of the Kidney (6th
Edition) [17], the pathologic diagnosis of secondary FSGS
requires that a glomerular lesion falls within the morpho-
logic spectrum of FSGS by light microscopy, but has seg-
mental or a less severe degree of foot process effacement
and/or electron dense deposits by electron microscopy,
with or without clinically identifiable causes of FSGS. The
13 patients with secondary FSGS include 2 tip variant, 10
NOS variant and 1 perihilar variant according to light mi-
croscopy. Of the thirteen patients with secondary FSGS,
there was one with pre-eclampsia, one with Kimura di-
sease, two with obesity, one with Alport syndrome, and
eight without identifiable factors. Compared to patients
with primary FSGS, patients with secondary FSGS had less
urine protein (3.7, inter-quartile range (IQR) 1.9 to 5.8
versus 7.7, IQR 5.4 to 13.3, P <0.001) and serum albumin
levels in the normal range.
Informed consent was obtained from each patient. The
design of this work was approved by the local clinical
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Hospital and was in compliance with the Declaration
of Helsinki.
Renal histopathology
Renal biopsy was performed at the time of diagnosis.
Renal specimens were evaluated with direct immuno-
fluorescence, light and electron microscopy, and were
forwarded to two pathologists. Both pathologists exam-
ined the biopsies separately, being blinded to each other
as well as to the patients’ clinical data. Differences in
diagnosis between the two pathologists were resolved by
re-reviewing the biopsies and coming to a consensus.
For direct immunofluorescence, immunoglobulin G
(IgG), IgM, IgA, C3c, C1q, fibrinogen and albumin were
detected by fluorescein isothiocyanate (FITC)-conjuga-
ted antibodies (Dako, Copenhagen, Denmark) on frozen
tissues. The fluorescence intensity was determined using
a semi-quantitative scale of 0 to 4+. For light micros-
copy, paraffin sections were stained with hematoxylin and
eosin, periodic acid-schiff, periodic acid-silver methena-
mine and Masson’s trichrome. For electron microscopy, in
brief, the tissue was fixed in 2.5% glutaraldehyde and 1%
osmium tetroxide, then dehydrated in graded acetone and
embedded in Epon 812. Ultrathin sections were cut at a
thickness of 80 nm and placed on nickel grids. Then, the
ultrathin sections were stained with uranyl acetate and ex-
amined by a transmission electron microscope JEM-1230
(JEOL, Tokyo, Japan).
Sample collection
Spot urine samples of patients were collected in the first
urination of the day of renal biopsy. The urine samples
from 26 age- and gender-matched healthy donors were
collected as normal controls. The urine, collected imme-
diately after centrifugation at 1,800 rpm for 15 minutes
at 4°C, was stored in aliquots at -80°C until use. Repea-
ted freeze/thaw cycles were avoided. Urine samples from
the 16 patients with follow up were also collected and
stored until use.
Quantification of urinary suPAR
We detected the concentration of urinary suPAR using
the Quantikine Human uPAR Immunoassay (R&D Sys-
tems, Minneapolis, MN, USA) following the manufac-
turer’s protocol. In brief, the principle of the assay is a
five-step procedure: (1) 96-well polystyrene microplates
were pre-coated with a mouse monoclonal antibody
against uPAR; (2) urine samples were diluted to 1:8 and
added to each well and incubated for two hours at room
temperature; (3) after incubation and washing, horseradish
peroxidase-conjugated polyclonal antibodies against uPAR
were added and incubated for two hours at roomtemperature; (4) after washing, substrate solution was
added to each well and incubated for 30 minutes at room
temperature protected from light; and (5) a stop solution
was added to each well and then the absorbance was re-
corded using an enzyme-linked immunosorbent assay
(ELISA) reader at 450/570 nm. The suPAR level of each
sample was calculated using Curve expert 1.3.Cell culture
Conditionally immortalized human podocytes were kindly
provided by Prof. Jochen Reiser (Rush University, Chicago,
IL, USA). To propagate podocytes, cells were cultivated
on Thermo Fisher Nunc plates (Thermo Fisher Scientific
Inc, Slangerup, Denmark) at 33°C in the presence of
Roswell Park Memorial Institute (RPMI)-1640 medium
(Life Technologies Corp, Grand Island, NY, USA), con-
taining 10% fetal bovine serum (Life Technologies Corp)
and 1% insulin-transferrin-selenium (Life Technologies
Corp). Cultured podocytes were seeded on coverslips
(Thermo Fisher Scientific Inc) and allowed to differentiate
for 14 days at the growth-restrictive temperature of 37°C
in the presence of RPMI-1640 medium containing 10%
fetal bovine serum before any treatment [18].
To study the activation effect of urinary suPAR on
podocytes, conventional podocyte medium was changed
to RPMI-1640 medium for 10 hours. Then, RPMI-1640
medium was changed into RPMI-1640 medium contain-
ing 5% urine from a patient with primary FSGS (a 44-
year old female patient with primary FSGS and NOS
variant, urinary suPAR levels: 450.98 pg/μmol Cr) at
presentation, which had been filtered with a 0.22μm fil-
ter. Recombinant human suPAR protein (R&D Systems)
was used at 1 μg/ml as a positive control [12]. RPMI-
1640 medium containing 5% normal urine, 5% urine
from a patient with minimal change disease (a 20-year old
woman with a urinary suPAR level of 236.21 pg/μmol Cr)
at presentation, 5% urine from a patient with membranous
nephropathy (a 47-year old woman with a urinary suPAR
level 215.37 pg/μmol Cr) at presentation, or 5% bovine
serum albumin filtered with a 0.22 μm filter and RPMI-
1640 medium containing nothing were used as controls.
To investigate whether the FSGS urine-induced podo-
cyte activation was due to the activation of the uPAR-
β3 integrin pathway, monoclonal uPAR antibodies (R&D
Systems, 1 μg/ml) were pre-incubated with the urine for
one hour at 37°C in a water bath before being added
to the podocytes. Forty-eight hours after treatment,
human podocytes were fixed with 4% paraformaldehyde
before immunofluorescence labeling. Urines from the
other two patients with primary FSGS (NOS variant and
cellular variant, respectively) with a higher level of urinary
suPAR at presentation were investigated under the same
conditions.
Table 1 The demographic and clinical parameters of
patients with primary FSGS
Parameters Number = 62
Age (years), (median, range) 28, 13 to 84
Gender (male/female) 42/20
Nephrotic syndrome, number (%) 59 (95.2%)
Acute kidney injury, number (%) 15 (24.2%)
Microscopic hematuria, number (%) 46 (74.2%)
24-hour urine protein (g/24 hour) (median, IQR) 7.7, 5.4 to 13.3
Albumin (g/L) (mean ± s.d.) 20.3 ± 5.9
Serum creatinine at presentation (μmol/l)
(median, IQR)
89.0, 64.8 to 135.4
Percentage of sclerosis in glomeruli (%) (mean ± s.d.) 16.1 ± 14.3
Percentage of segmental sclerosis in glomeruli (%)
(mean ± s.d.)
11.7 ± 11.6
Percentage of global-sclerosis in glomeruli (%)
(mean ± s.d.)
1.8 ± 4.1
Crescents formation, number (%) 9 (14.5%)
FSGS, focal segmental glomerulosclerosis; IQR, inter-quartile range; s.d.,
standard deviation.
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integrin in human podocytes
The activity of β3 integrin of human podocytes is mea-
sured using the activation epitope–recognizing anti-
body AP5 (GTI Diagnostics, San Diego, CA, USA). In
brief, fixed podocytes were washed three times with
0.01 Mol/L phosphate buffered saline, pH 7.4, permeabi-
lized with 0.1% Triton X-100 (Sigma, Munich, Germany)
in phosphate-buffered saline. To block non-specific stain-
ing, sections were incubated with 3% bovine serum albu-
min in phosphate-buffered saline for 30 minutes at room
temperature. The primary antibody AP5 (dilution 1:50 in
phosphate-buffered saline) was added to each coverslip
directly. Antibodies were incubated overnight at 4°C. After
sufficient wash with phosphate-buffered saline (pH 7.4)
(five minutes, three times), Cy3-labeled donkey anti-
mouse IgG (The Jackson Laboratory, West Grove, PA,
USA, and dilution 1:400) was added and incubated for
one hour at room temperature protected from light. The
coverslip was then washed with phosphate-buffered saline
and counter stained with 4’,6-diamidino-2-phenylindole
(DAPI, 3 mM, Life Technologies Corp) for five minutes.
Finally, sections were stored briefly at 4°C before being
examined using an immunofluorescence microscope
(Nikon Eclipse 80i, Tokyo, Japan). Negative controls were
performed by omitting or replacing the primary anti-
bodies. All the photos were taken with the same magnifi-
cation (×400) and exposure time (800 milliseconds).
Statistical analysis
Statistical analysis was performed using statistical soft-
ware SPSS 16.0 (SPSS Inc., Chicago, IL, USA). Compari-
son of quantitative parameters was assessed using the
non-parametric test between two non-normally distrib-
uted variables or one normally with one non-normally
distributed variable. Comparison of paired variables was
assessed using the paired samples t test (for data that were
normally distributed) or paired samples non-parametric
test (for data that were not normally distributed). Spear-
man’s correlation test was used to measure the correlation
between two non-normally distributed variables or one
normally with one non-normally distributed variable. All
statistical analyses were two-tailed and P <0.05 was con-
sidered as significant.
Results
Demographic and clinical characteristics of patients with
primary FSGS
The median age of the 62 patients with primary FSGS
was 28 years, ranging from 13 to 84 years old. Forty-two
were men and 20 were women. Their demographic, cli-
nical and pathological data are listed in Table 1. Of the
62 patients, 59 had nephrotic syndrome (95.2%), 15 had
acute kidney injury (24.2%), and 46 had microscopichematuria (74.2%). Their median urine protein was 7.7
(IQR 5.4 to 13.3) g/24 hours. The mean serum albumin
was 20.3 ± 5.9 g/L. The median serum creatinine was
89.0 (IQR 64.8 to 135.4) μmol/L at presentation.
The urinary suPAR levels in patients with primary FSGS
and controls
As molecular weights of suPAR fragments range from
22 to 45 kDa, these molecules could pass through the
glomerular filtration barrier, and prior literature has also
reported that the urinary suPAR level is correlated with
the creatinine concentration [16]. So, in our study, the
urinary suPAR levels were normalized by urinary cre-
atinine levels to correct for differences in dilution, and
the urinary suPAR levels were calculated by the ratio
of urinary concentration of suPAR to the urinary cre-
atinine concentration. The urinary suPAR levels of
patients with primary FSGS, minimal change disease,
membranous nephropathy, secondary FSGS and nor-
mal subjects are shown in Table 2 and Figure 1. The
urinary suPAR level of patients with primary FSGS
(500.56, IQR 262.78 to 1,059.44 pg/μmol creatinine (Cr))
is significantly higher than that of patients with minimal
change disease (307.86, IQR 216.54 to 480.18 pg/μmol Cr,
P = 0.033), membranous nephropathy (250.23, IQR 170.37
to 357.59 pg/μmol Cr, P <0.001), secondary FSGS (220.45,
IQR 149.38 to 335.54 pg/μmol Cr, P <0.001) and nor-
mal subjects (183.59, IQR 103.92 to 228.78 pg/μmol Cr,
P <0.001).
Using the mean plus two standard deviations of the
urinary suPAR levels from the normal subjects as a cut-
off value at 342.02 pg/μmol Cr, we found that 42 of the
Table 2 The demographic data and urinary suPAR levels of patients and controls




Secondary FSGS Normal control
Number of subjects 62 13 22 13 26
Age (median, range) 28, 13 to 84 46, 18 to 71 50, 40 to 78 40, 15 to 46 27, 22 to 47













FSGS, focal segmental glomerulosclerosis; IQR, inter-quartile range; suPAR, soluble urokinase receptor.
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cutoff value, but only 3 in the 22 with membranous ne-
phropathy (13.6%), 4 in the 13 with minimal change dis-
ease (30.8%) and 1 in 26 normal controls (3.8%) were
above the cutoff value.
The association between plasma and urinary suPAR levels
Plasma suPAR levels of patients with primary FSGS and
controls were measured and reported in our previous
study [13]. There were 59 patients with primary FSGS,
13 patients with minimal change disease, 22 patients
with membranous nephropathy, 13 patients with sec-
ondary FSGS and 26 normal subjects with both plasma
and urinary suPAR levels. Plasma and urinary suPAR
levels were positively correlated in patients with primary
FSGS (r = 0.431, P = 0.001), but were not correlated in pa-
tients with minimal change disease (r = 0.121, P = 0.694),Figure 1 Urinary suPAR levels among patients with primary
FSGS, minimal change disease, membranous nephropathy,
secondary FSGS and normal subjects. FSGS, focal segmental
glomerulosclerosis; suPAR, soluble urokinase receptor.membranous nephropathy (r = 0.143, P = 0.526), secon-
dary FSGS (r = 0.088, P = 0.775) nor normal subjects
(r = 0.303, P = 0.132).
The urinary suPAR levels in patients with primary FGGS
with different pathological variants
We compared the urinary suPAR levels among different
histopathological variants of patients with primary FSGS.
As shown in Figure 2, the urinary suPAR level of cellular
variant (995.51, IQR 400.61 to 1,558.72 pg/μmol Cr) was
significantly higher than that of tip variant (373.42, IQR
242.72 to 647.62 pg/μmol Cr, P = 0.002); although it was
also higher than that of NOS variant, the difference was
not significant (344.08, IQR 260.30 to 1,073.42 pg/μmol Cr,
P = 0.06). The urinary suPAR level of the patient with peri-
hilar variant was 2,269.13 pg/μmol Cr and the patient with
advanced FSGS was 239.06 pg/μmol Cr.
Further analysis showed that nearly all the patients
with tip variant had lower urinary suPAR levels whichFigure 2 The urinary suPAR levels in primary FSGS patients
with different pathological variants. FSGS, focal segmental
glomerulosclerosis; suPAR, soluble urokinase receptor.
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(373.42, IQR 242.72 to 647.62 pg/μmol Cr versus 307.86,
IQR 216.54 to 480.18 pg/μmol Cr, P = 0.367).
The associations between urinary suPAR levels and
clinical, laboratory data of patients with primary FSGS
In our study, it is of great interest to note that the urinary
suPAR levels in patients with primary FSGS were po-
sitively correlated with 24-hour urine protein (r = 0.287,
P = 0.024) (Figure 3A) and the erythrocyte sedimenta-
tion rate (r = 0.579, P <0.001) but were negatively cor-
related with plasma albumin (r = -0.269, P = 0.034) and
hemoglobin (r = -0.400, P = 0.001). There was no sig-
nificant correlation between urinary suPAR levels and
C-reactive protein (CRP) (r = 0.242, P = 0.156). Further-
more, urinary suPAR levels in patients with minimal
change disease (r = 0.192, P = 0.529) (Figure 3B), mem-
branous nephropathy (r = -0.189, P = 0.399) (Figure 3C)
and secondary FSGS (r = -0.264, P = 0.384) (Figure 3D)
were not significantly correlated with 24-hour urine
protein.
We further performed correlation analysis between urin-
ary suPAR levels and estimated glomerular filtration rate
(eGFR) for each individual glomerular disease (Figure 4).
There was no correlation between the urinary suPAR levels
and eGFR in patients with primary FSGS (r = -0.158, P =
0.221) (Figure 4A), minimal change disease (r = -0.159, P =
0.603) (Figure 4B), membranous nephropathy (r = -0.290,
P = 0.191) (Figure 4C) or secondary FSGS (r = -0.126, P =
0.681) (Figure 4D).
The change of urinary suPAR levels at presentation and
during follow up of patients with primary FSGS
During follow up with a mean duration of 80.0 (IQR
22.0 to 123.0) weeks, we collected urine samples from
16 patients with therapeutic responses. There were eight
patients achieving complete remission, three patientsFigure 3 The correlation between urinary suPAR levels and 24-hour u
change disease; C. Patients with membranous nephropathy; D. Patients wit
soluble urokinase receptor.achieving partial remission and five patients with treat-
ment failure. At presentation, the median urinary suPAR
levels of the three groups were not significantly different
(661.19, IQR 224.32 to 1,115.29 pg/μmol Cr versus
265.00, IQR 115.73 to 291.77 pg/μmol Cr versus 256.14,
IQR 224.88 to 397.53 pg/μmol Cr, P = 0.320, respectively).
During follow up, the median urinary suPAR levels of the
three groups were 217.68, IQR 121.77 to 415.55 pg/μmol
Cr, 296.17, IQR 163.18 to 659.49 pg/μmol Cr and 318.22,
IQR 266.32 to 628.65 pg/μmol Cr, respectively. In order to
perform statistical analysis, we combined the partial
remission group and the treatment failure group into
a non-complete remission group. At presentation, the
median urinary suPAR levels of patients achieving com-
plete remission and non-complete remission were not
significantly different (661.19, IQR 224.32 to 1,115.29
pg/μmol Cr versus 260.56, IQR 209.51 to 331.00 pg/μmol
Cr, P = 0.093). Interestingly, the median urinary suPAR
level of patients with complete remission decreased sig-
nificantly (661.19, 224.32 to 1,115.29 pg/μmol Cr ver-
sus 217.68, IQR 121.77 to 415.55 pg/μmol Cr, P = 0.017)
(Figure 5A), while for patients with non-complete remis-
sion, the mean urinary suPAR level increased signifi-
cantly (271.68 ± 99.05 pg/μmol Cr versus 403.38 ± 201.55
pg/μmol Cr, P = 0.031) (Figure 5B). To compare with
eGFR at presentation with that at follow up, we performed
correlation analysis between the change of urinary suPAR
levels and the change of eGFR in primary FSGS patients
with complete remission (r = 0.214, P = 0.645) and non-
complete remission (r = 0.571, P = 0.180). There was no
correlation between the changes in suPAR and the chan-
ges in eGFR.
Urinary suPAR could bind and activate β3 integrin in
podocytes
In our study, we found that urinary suPAR levels in pa-
tients with primary FSGS were obviously higher thanrine protein. A. Patients with primary FSGS; B. Patients with minimal
h secondary FSGS. FSGS, focal segmental glomerulosclerosis; suPAR,
Figure 4 The correlations between urinary suPAR levels and estimated glomerular filtration rate for each individual glomerular
disease. A. Patients with primary FSGS; B. Patients with minimal change disease; C. Patients with membranous nephropathy; D. Patients with
secondary FSGS. FSGS, focal segmental glomerulosclerosis; suPAR, soluble urokinase receptor.
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branous nephropathy and normal subjects. Previous stu-
dy has shown that suPAR can interact with β3 integrin.
So we hypothesized that the elevated urinary suPAR le-
vels in patients with primary FSGS might be pathogenic,
and the urinary suPAR from patients with primary FSGS
might induce podocyte injury via activating β3 integrin
in cultured human podocytes.
The human differentiated podocytes were incubated
and cultured with urine from an index patient with pri-
mary FSGS at presentation. The recombinant suPAR,
normal urine, bovine serum albumin and RMPI 1640
were used as controls. A blocking antibody to uPAR was
used to confirm the activation effect of urinary suPAR
on human podocytes. After 48 hour incubation, immu-
nofluorescence staining was performed to analyze the
expression and localization of the AP5 signal which cor-
responds to activated β3 integrin. The AP5 signal was
strongly induced and expressed along the cell membrane
when human differentiated podocytes were incubatedFigure 5 The changes of urinary suPAR levels in patients with
primary FSGS during follow up. A. Patients with complete
remission; B. Patients with non-complete remission. FSGS, focal
segmental glomerulosclerosis; suPAR, soluble urokinase receptor.with FSGS urine (Figure 6I) and recombinant suPAR
(Figure 6G). However, the AP5 signal could be signifi-
cantly reduced when FSGS urine and recombinant suPAR
were previously incubated with the uPAR blocking anti-
body (Figure 6J, Figure 6H, respectively). Urines from the
other two patients with primary FSGS with higher urinary
suPAR levels at presentation confirmed the results. These
data suggest that urinary suPAR could activate β3 integrin
of human podocytes specifically. In contrast, the AP5 sig-
nal was very weak when human podocytes were incubated
with normal urine (Figure 6E), urine from a patient with
minimal change disease (Figure 6K), urine from a patient
with membranous nephropathy (Figure 6M), bovine se-
rum albumin (Figure 6B) and RPMI 1640 (Figure 6C), and
the signal was not significantly influenced after the ad-
dition of the blocking antibody (Figure 6F, Figure 6L,
Figure 6N, Figure 6D, respectively). Furthermore, the
weak AP5 signal of podocytes incubated with RPMI
1640 combined with the blocking antibody (Figure 6D)
indicated that this antibody did not influence the activa-
tion of β3 integrin. The details are shown in Figure 6.
Discussion
FSGS is a major pathologic type of refractory nephrotic
syndrome of children and adults, and a major cause of
end-stage renal disease, with an estimated incidence of
seven per million [2]. It is now regarded as a clinical–
pathologic syndrome that has common glomerular lesions
but is mediated by diverse causes. It includes a primary
form of unknown causes and a form secondary to many
other conditions, including drug toxicity, viruses, meta-
bolic disorders and so on. During the past two decades,
much evidence has revealed that there might be causative
circulating factors in patients with primary FSGS [10,11].
In 2011, Wei et al. proposed serum suPAR as a possible
cause of two-thirds of primary FSGS cases with renal
transplantation for the first time [12]. They also validated
the importance of serum suPAR in two discrete cohorts of
children and young adults with biopsy-proven primary
FSGS - the North America-based FSGS clinical trial (CT)
Figure 6 AP5 immunofluorescence staining of differentiated human podocytes incubated with different additional materials. A. AP5
antibody replaced by phosphate-buffered saline; B. Podocytes incubated with bovine serum albumin; C. Podocytes incubated with RPMI 1640;
D. Podocytes incubated with RPMI 1640 combined with blocking antibody; E. Podocytes incubated with normal urine; F. Podocytes incubated
with normal urine combined with blocking antibody; G. Podocytes incubated with recombinant human suPAR protein; H. Podocytes incubated
with recombinant human suPAR protein combined with blocking antibody; I. Podocytes incubated with urine from patients with primary FSGS;
J. Podocytes incubated with urine from patients with primary FSGS combined with blocking antibody; K. Podocytes incubated with urine from a
patient with minimal change disease; L. Podocytes incubated with urine from a patient with minimal change disease combined with blocking
antibody; M. Podocytes incubated with urine from a patient with membranous nephropathy; N. Podocytes incubated with urine from a patient
with membranous nephropathy combined with blocking antibody. FSGS, focal segmental glomerulosclerosis; suPAR, soluble urokinase receptor.
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resistant nephrotic syndrome (PodoNet) [19]. They also
found increased circulating suPAR levels in a mother with
FSGS and her newborn with a transient proteinuria [20].
Our previous study also revealed that plasma suPAR levels
were elevated in more than half of patients with primary
FSGS and were associated with treatment response [13].
However, the role of suPAR in primary FSGS has been a
subject of controversy; some studies claimed that the
serum suPAR level could not reliably predict response to
treatment [14], and it was unlikely the leading cause for
childhood primary FSGS [15]. Recently, Franco Palacios
et al. reported that urinary suPAR levels but not serum
suPAR levels in renal transplant recipients with FSGS re-
currence before transplantation were higher than those in
recipients with IgA nephropathy, membranous nephropa-
thy, diabetic nephropathy and autosomal dominant poly-
cystic kidney disease [16]. They indicated that the urinary
suPAR level might be useful in predicting the recur-
rence of FSGS after transplantation [16]. Therefore, itis important to further investigate the role of suPAR
in primary FSGS.
In the current study, we measured the urinary suPAR
levels, on the same day as renal biopsy, in a Chinese co-
hort of patients with biopsy-proven primary FSGS and
controls, and further analyzed the association between
urinary suPAR levels and clinical parameters. Further-
more, we confirmed that suPAR in urine of patients with
primary FSGS could induce β3 integrin activation in cul-
tured human podocytes which leads to injury of the
podocytes.
In the present study of our 62 patients with primary
FSGS, their urinary suPAR levels were significantly higher
than those of normal subjects, patients with minimal
change disease, membranous nephropathy and secondary
FSGS. In the same cohort of patients with primary FSGS,
we found that the urinary suPAR levels of 67.7% patients
with primary FSGS were above the cutoff value of normal
subjects, but the plasma suPAR levels of only 54.1% were
above the cutoff value. Further analysis indicated that the
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tively correlated in patients with primary FSGS, but not in
disease controls and normal subjects. These data suggest
that, in comparison with plasma suPAR, urinary suPAR
might be a better biomarker to distinguish different dis-
eases. More importantly, we found that the urinary suPAR
levels at presentation were positively correlated with 24-
hour urine protein and negatively correlated with plasma
albumin levels in patients with primary FSGS. These data
provide strong evidence that urinary suPAR might not
only be a biomarker but also a pathogenic contributor to
the pathogenesis of primary FSGS.
We have some speculations about the better differenti-
ation performance of suPAR in urine than serum: 1)
Urinary suPAR was presented as the ratio of suPAR over
urine creatinine. This might make eGFR less a confoun-
der in differential diagnosis. 2) Wei et al. and Zhang et al.
have reported that the podocyte itself could produce lipid
raft-associated uPAR and the uPAR-β3-integrin signaling
participated in podocyte injury and proteinuria production
[21,22]. Urinary suPAR levels represent both circulating
and podocyte generated suPAR, so it may separate FSGS
much more clearly. 3) suPAR consists of intact molecules
and various segments. The pathogenic fragment has not
been fully elucidated and commercial ELISA kits were
used to detect all fragments. suPAR is a highly glycosyl-
ated protein. The glomerular filtration barrier might have
charge selectivity to suPAR. The pathogenic suPAR might
be more easily filtered through the glomerular basement
membrane, binding on podocytes and concentrated in
urine. This might make urinary suPAR more clinically sig-
nificant. 4) The effect of suPAR on podocytes exhibited
somewhat dose-dependent characteristics. We speculate
that there might be a threshold for suPAR to induce podo-
cyte injury in primary FSGS. The threshold might reduce
the overlapping results shown in serum suPAR and enable
the urinary suPAR to separate FSGS clearly.
FSGS has several pathological phenotypes or variants
which might indicate various pathophysiological mecha-
nisms. Our previous study indicated that the plasma
suPAR levels, at the time of renal biopsy, were higher in
patients with cellular variant than in those with tip and
NOS variants, although the difference was not signifi-
cant [13]. In this study, we found that urinary suPAR
levels in patients with cellular variants were indeed sig-
nificantly higher than those of patients with tip variant.
Interestingly, our further analysis showed that the urinary
suPAR levels were comparable between primary FSGS pa-
tients with tip variant and patients with minimal change
disease. Previous studies had demonstrated that patients
with tip variant showed the highest rate of treatment re-
mission and lowest rate of end-stage renal disease com-
pared with patients with other variants, while patients
with cellular variant had higher proteinuria than patientswith tip variant and NOS variant [23-25]. So we specu-
lated that suPAR might be associated with different patho-
logical lesions in patients with primary FSGS, which needs
further investigation.
In order to demonstrate the pathogenic role of urinary
suPAR in patients with primary FSGS, we investigated
the activation effect of urinary suPAR on its ligand (AP5
staining), β3 integrin, in cultured human differentiated
podocytes [21,22]. Our data showed that the AP5 signal
was strongly induced and expressed along the cell mem-
brane when podocytes were incubated with urine of pa-
tients with primary FSGS and recombinant suPAR, but
the AP5 signal was very weak when podocytes were in-
cubated with normal urine, bovine serum albumin or
RPMI 1640. These results indicated that some soluble
factor, probably elevated suPAR in the urine of patients
with primary FSGS, actived the β3 integrin. More im-
portantly, the urine-induced β3 integrin activation of
podocytes could be reduced by a blocking antibody spe-
cific to uPAR. This demonstrated the specificity of urinary
suPAR-induced β3 integrin activation in cultured human
podocytes. Previous studies have proven that activa-
tion of β3 integrin is important to induce increased
podocyte motility and foot process effacement caused
proteinuria and FSGS in a mouse model [21]. So we
could speculate that, at least from our study, suPAR
in some patients with primary FSGS might induce po-
docyte injury via the activation of β3 integrin in podocytes,
and this phenomenon suggests that suPAR might be one
of the permeability factors for at least some patients with
primary FSGS.
In this study, we also found that the urinary suPAR
level at presentation was not associated with therapeutic
response, which was consistent with Maas’s study and
our previous study about plasma suPAR in patients with
primary FSGS [13,14]. However, our previous study indi-
cated that, in a small group of patients with treatment
and follow up data, the elevated plasma suPAR could
significantly decrease in patients who achieved complete
remission [13]. In this study, it was found that the ele-
vated urinary suPAR levels also decreased significantly in
patients with complete remission, but not in those with-
out complete remission. These findings indicated again
that suPAR might be involved in the pathogenesis of pri-
mary FSGS. However, our studies had a relatively small
size of patients with follow up data; a further large co-
hort study is needed to validate this phenomena.
Previous studies reported that suPAR levels were in-
creased during infection and inflammation [26-29]. We
analyzed the association between urinary suPAR levels
and CRP, a sensitive biomarker of inflammatory status,
but no correlation between urinary suPAR levels and
CRP was identified, which is in accordance with a previ-
ous study [19]. This indicated that inflammation was not
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our patients with primary FSGS.
uPAR, the glycosylphosphatidylinositol (GPI)-anchored
protein with three domains (DI, DII, and DIII), is ex-
pressed on several different cell types, including neutro-
phils, monocytes, macrophages, activated T-lymphocytes,
endothelial cells and kidney podocytes [30-32]. It could be
released to plasma as suPAR after being cleaved of the
GPI anchor, and it is also susceptible to cleavage at the
linker region between DI and DII, so both the whole re-
ceptor and various segments of it are found free in the
serum and are all called suPAR [33,34]. In addition to
regulation of proteolysis, suPAR initiates signaling trans-
duction in cooperation with other transmembrane pro-
teins, such as integrins, caveolin and G-protein-coupled
receptors, which promotes cell proliferation, invasion, mo-
tility and survival [35-37]. However, the pathogenic do-
main or part of the suPAR molecule in FSGS is not fully
elucidated; it might be a specific domain, or a special form
of glycosylation or phosphorylation of this interesting
molecule. Although our results suggest that suPAR might
play an important role in the pathogenesis of primary
FSGS, there was still an overlap of urinary suPAR levels
between patients with primary FSGS and patients with
secondary FSGS and other glomerular diseases. In ad-
dition, various forms of the suPAR molecule exist in both
plasma and urines in physiological conditions. However,
the commercial ELISA kits used could not distinguish
among these forms. Further studies are needed to identify
the pathogenic part of the complex molecule and specific
assays to detect pathogenic suPAR are needed.Conclusions
In conclusion, urinary suPAR was specifically elevated in
patients with primary FSGS and was associated with dis-
ease severity. The urinary suPAR could activate β3 integ-
rin of human podocytes.Competing interests
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